Tier 3 — preclinical

Minoxidil use in dermatology, side effects and recent patents

Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S
Recent Patents on Inflammation & Allergy Drug Discovery 2012 6(2):130-136

Bibliography

PubMed
PMID 22409453
DOI
10.2174/187221312800166859
Funding
Not stated in the available abstract.
Competing interests
Not stated in the available abstract.

Study snapshot

DesignNarrative review
ModelHuman (summarising established clinical use)
SampleNot applicable (review)
InterventionTopical/oral minoxidil, established dermatological use
DurationNot applicable (review)
EndpointsHair regrowth; Adverse effects (contact dermatitis); Mechanism of action

What the study showed, in plain terms

This review summarises minoxidil's well-established use for hair loss, its likely mechanism (widening blood vessels and opening potassium channels to improve follicle blood supply), and its most common side effect, scalp irritation.

Key findings

Minoxidil is a well-established topical (2% or 5%) treatment for androgenic alopecia, requiring continued regular use to maintain results. Its mechanism is not fully understood but is thought to involve vasodilation and potassium-channel opening. The most common adverse effects are irritant and allergic contact dermatitis on the scalp.

What this study can and cannot tell us

Narrative review, not a systematic review or new trial. Not related to fisetin — used here only as the established evidence-based comparator for hair loss treatment.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology